STOCK TITAN

[Form 4/A] GeneDx Holdings Corp. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

GeneDx Holdings (WGS) – Amended Form 4 (filed 08-07-25)

Director and 10 % owner Eli Casdin reported the vesting and immediate settlement of 12,924 RSUs on 06-18-25, converting to Class A common shares at $0 exercise cost. Following the event, Casdin now holds 20,518 shares directly and, through various affiliated entities, 3.86 million shares indirectly (3,507,164 via Casdin Partners Master Fund LP, 333,144 via CMLS Holdings LLC, and 19,247 via Casdin Partners GP LLC).

The amendment corrects prior clerical errors: earlier filings over-stated direct holdings by 1,376 shares and under-stated them by 4,452 shares in separate periods. No open-market purchases or sales occurred; transactions solely reflect RSU vesting. The RSUs will continue to vest on the earlier of the next annual meeting or one-year anniversary, contingent on service.

Investor takeaway: The filing increases disclosure accuracy but does not involve cash transactions or alter the overall economic exposure of this significant insider.

GeneDx Holdings (WGS) – Modifica al Modulo 4 (depositato il 25-07-08)

Il direttore e proprietario del 10%, Eli Casdin, ha comunicato il vesting e il regolamento immediato di 12.924 RSU il 18-06-25, convertite in azioni ordinarie di Classe A con costo di esercizio pari a 0 $. Dopo l'evento, Casdin detiene ora 20.518 azioni direttamente e, tramite varie entità affiliate, 3,86 milioni di azioni indirettamente (3.507.164 tramite Casdin Partners Master Fund LP, 333.144 tramite CMLS Holdings LLC e 19.247 tramite Casdin Partners GP LLC).

La modifica corregge errori di natura amministrativa precedenti: le comunicazioni precedenti avevano sovrastimato le partecipazioni dirette di 1.376 azioni e le avevano sottostimate di 4.452 azioni in periodi differenti. Non si sono verificate operazioni di acquisto o vendita sul mercato aperto; le transazioni riflettono esclusivamente il vesting delle RSU. Le RSU continueranno a maturare alla prima tra la prossima assemblea annuale o il primo anniversario, a condizione che il servizio continui.

Conclusione per gli investitori: la comunicazione migliora la precisione delle informazioni senza coinvolgere transazioni in denaro o modificare l'esposizione economica complessiva di questo importante insider.

GeneDx Holdings (WGS) – Formulario 4 enmendado (presentado el 25-07-08)

El director y propietario del 10%, Eli Casdin, reportó la consolidación y liquidación inmediata de 12,924 RSU el 18-06-25, convertidas en acciones ordinarias Clase A con costo de ejercicio de $0. Tras este evento, Casdin posee ahora 20,518 acciones directamente y, a través de varias entidades afiliadas, 3.86 millones de acciones indirectamente (3,507,164 a través de Casdin Partners Master Fund LP, 333,144 a través de CMLS Holdings LLC, y 19,247 a través de Casdin Partners GP LLC).

La enmienda corrige errores administrativos previos: presentaciones anteriores sobreestimaron las participaciones directas en 1,376 acciones y las subestimaron en 4,452 acciones en diferentes períodos. No hubo compras ni ventas en el mercado abierto; las transacciones reflejan únicamente el vesting de las RSU. Las RSU continuarán consolidándose en la primera de la próxima junta anual o el aniversario de un año, condicionado al servicio.

Conclusión para inversores: el informe mejora la precisión de la divulgación pero no implica transacciones en efectivo ni altera la exposición económica total de este importante insider.

GeneDx Holdings (WGS) – 수정된 양식 4 (2025-08-07 제출)

이사이자 10% 소유주인 Eli Casdin은 2025년 6월 18일에 12,924 RSU의 베스팅 및 즉시 정산을 보고했으며, 이는 행사가격 $0로 클래스 A 보통주로 전환되었습니다. 이 사건 이후 Casdin은 직접 20,518주를 보유하고 있으며, 여러 계열사를 통해 간접적으로 386만 주를 보유하고 있습니다(3,507,164주는 Casdin Partners Master Fund LP, 333,144주는 CMLS Holdings LLC, 19,247주는 Casdin Partners GP LLC를 통해).

이번 수정은 이전의 사무적 오류를 바로잡은 것으로, 이전 제출서류에서는 직접 보유 주식이 1,376주 과대계상되고 4,452주 과소계상된 기간이 있었습니다. 공개 시장에서 매매는 없었으며, 거래는 전적으로 RSU 베스팅을 반영합니다. RSU는 다음 연례 회의 또는 1주년 중 빠른 시점에 계속 베스팅되며, 근무 조건에 따라 달라집니다.

투자자에게 드리는 요점: 이번 제출은 공시 정확성을 높였으나 현금 거래나 이 주요 내부자의 경제적 노출에 변화는 없습니다.

GeneDx Holdings (WGS) – Formulaire 4 modifié (déposé le 25-07-08)

Le directeur et détenteur de 10 % Eli Casdin a déclaré la cession et le règlement immédiat de 12 924 RSU le 18-06-25, converties en actions ordinaires de classe A à coût d'exercice nul. Suite à cet événement, Casdin détient désormais 20 518 actions en direct et, via diverses entités affiliées, 3,86 millions d’actions indirectement (3 507 164 via Casdin Partners Master Fund LP, 333 144 via CMLS Holdings LLC, et 19 247 via Casdin Partners GP LLC).

La modification corrige des erreurs administratives antérieures : les déclarations précédentes avaient surestimé les participations directes de 1 376 actions et les avaient sous-estimées de 4 452 actions à différentes périodes. Aucun achat ou vente sur le marché ouvert n’a eu lieu ; les transactions reflètent uniquement le vesting des RSU. Les RSU continueront de se vester à la date la plus proche entre la prochaine assemblée annuelle ou le premier anniversaire, sous condition de service.

À retenir pour les investisseurs : ce dépôt améliore la précision des informations sans impliquer de transactions en espèces ni modifier l’exposition économique globale de cet initié important.

GeneDx Holdings (WGS) – Geändertes Formular 4 (eingereicht am 25.07.08)

Direktor und 10%-Eigentümer Eli Casdin meldete die Vesting und sofortige Abwicklung von 12.924 RSUs am 18.06.25, die in Stammaktien der Klasse A mit Ausübungskosten von 0 $ umgewandelt wurden. Nach diesem Ereignis hält Casdin nun 20.518 Aktien direkt und über verschiedene verbundene Unternehmen 3,86 Millionen Aktien indirekt (3.507.164 über Casdin Partners Master Fund LP, 333.144 über CMLS Holdings LLC und 19.247 über Casdin Partners GP LLC).

Die Änderung korrigiert frühere administrative Fehler: Frühere Meldungen überschätzten die direkten Bestände um 1.376 Aktien und unterschätzten sie um 4.452 Aktien in verschiedenen Zeiträumen. Es gab keine Käufe oder Verkäufe am offenen Markt; die Transaktionen spiegeln ausschließlich das Vesting der RSUs wider. Die RSUs werden weiterhin zum früheren Zeitpunkt der nächsten Jahreshauptversammlung oder des einjährigen Jubiläums vesten, abhängig vom Dienstverhältnis.

Für Investoren: Die Meldung erhöht die Genauigkeit der Offenlegung, beinhaltet jedoch keine Bartransaktionen und ändert nicht die wirtschaftliche Gesamtexponierung dieses bedeutenden Insiders.

Positive
  • Insider maintains significant ownership (≈3.9 M shares), indicating continued alignment with shareholders.
  • Amendment increases transparency by correcting prior share-count inaccuracies.
Negative
  • Repeated clerical errors in previous filings may signal weaknesses in internal compliance processes.

Insights

TL;DR: Clerical fixes and RSU vesting; minimal market impact.

The amendment primarily rectifies share-count errors, enhancing filing accuracy but leaving the insider’s economic stake essentially unchanged. The 12,924-share RSU conversion is routine compensation and cash-neutral. With roughly 3.9 million shares under control, Casdin remains a key long-term holder, which can be interpreted as alignment with shareholder interests. However, repeated clerical mistakes raise minor concerns about internal reporting controls. Given the absence of open-market buying or selling, we view the disclosure as governance-neutral for valuation purposes.

GeneDx Holdings (WGS) – Modifica al Modulo 4 (depositato il 25-07-08)

Il direttore e proprietario del 10%, Eli Casdin, ha comunicato il vesting e il regolamento immediato di 12.924 RSU il 18-06-25, convertite in azioni ordinarie di Classe A con costo di esercizio pari a 0 $. Dopo l'evento, Casdin detiene ora 20.518 azioni direttamente e, tramite varie entità affiliate, 3,86 milioni di azioni indirettamente (3.507.164 tramite Casdin Partners Master Fund LP, 333.144 tramite CMLS Holdings LLC e 19.247 tramite Casdin Partners GP LLC).

La modifica corregge errori di natura amministrativa precedenti: le comunicazioni precedenti avevano sovrastimato le partecipazioni dirette di 1.376 azioni e le avevano sottostimate di 4.452 azioni in periodi differenti. Non si sono verificate operazioni di acquisto o vendita sul mercato aperto; le transazioni riflettono esclusivamente il vesting delle RSU. Le RSU continueranno a maturare alla prima tra la prossima assemblea annuale o il primo anniversario, a condizione che il servizio continui.

Conclusione per gli investitori: la comunicazione migliora la precisione delle informazioni senza coinvolgere transazioni in denaro o modificare l'esposizione economica complessiva di questo importante insider.

GeneDx Holdings (WGS) – Formulario 4 enmendado (presentado el 25-07-08)

El director y propietario del 10%, Eli Casdin, reportó la consolidación y liquidación inmediata de 12,924 RSU el 18-06-25, convertidas en acciones ordinarias Clase A con costo de ejercicio de $0. Tras este evento, Casdin posee ahora 20,518 acciones directamente y, a través de varias entidades afiliadas, 3.86 millones de acciones indirectamente (3,507,164 a través de Casdin Partners Master Fund LP, 333,144 a través de CMLS Holdings LLC, y 19,247 a través de Casdin Partners GP LLC).

La enmienda corrige errores administrativos previos: presentaciones anteriores sobreestimaron las participaciones directas en 1,376 acciones y las subestimaron en 4,452 acciones en diferentes períodos. No hubo compras ni ventas en el mercado abierto; las transacciones reflejan únicamente el vesting de las RSU. Las RSU continuarán consolidándose en la primera de la próxima junta anual o el aniversario de un año, condicionado al servicio.

Conclusión para inversores: el informe mejora la precisión de la divulgación pero no implica transacciones en efectivo ni altera la exposición económica total de este importante insider.

GeneDx Holdings (WGS) – 수정된 양식 4 (2025-08-07 제출)

이사이자 10% 소유주인 Eli Casdin은 2025년 6월 18일에 12,924 RSU의 베스팅 및 즉시 정산을 보고했으며, 이는 행사가격 $0로 클래스 A 보통주로 전환되었습니다. 이 사건 이후 Casdin은 직접 20,518주를 보유하고 있으며, 여러 계열사를 통해 간접적으로 386만 주를 보유하고 있습니다(3,507,164주는 Casdin Partners Master Fund LP, 333,144주는 CMLS Holdings LLC, 19,247주는 Casdin Partners GP LLC를 통해).

이번 수정은 이전의 사무적 오류를 바로잡은 것으로, 이전 제출서류에서는 직접 보유 주식이 1,376주 과대계상되고 4,452주 과소계상된 기간이 있었습니다. 공개 시장에서 매매는 없었으며, 거래는 전적으로 RSU 베스팅을 반영합니다. RSU는 다음 연례 회의 또는 1주년 중 빠른 시점에 계속 베스팅되며, 근무 조건에 따라 달라집니다.

투자자에게 드리는 요점: 이번 제출은 공시 정확성을 높였으나 현금 거래나 이 주요 내부자의 경제적 노출에 변화는 없습니다.

GeneDx Holdings (WGS) – Formulaire 4 modifié (déposé le 25-07-08)

Le directeur et détenteur de 10 % Eli Casdin a déclaré la cession et le règlement immédiat de 12 924 RSU le 18-06-25, converties en actions ordinaires de classe A à coût d'exercice nul. Suite à cet événement, Casdin détient désormais 20 518 actions en direct et, via diverses entités affiliées, 3,86 millions d’actions indirectement (3 507 164 via Casdin Partners Master Fund LP, 333 144 via CMLS Holdings LLC, et 19 247 via Casdin Partners GP LLC).

La modification corrige des erreurs administratives antérieures : les déclarations précédentes avaient surestimé les participations directes de 1 376 actions et les avaient sous-estimées de 4 452 actions à différentes périodes. Aucun achat ou vente sur le marché ouvert n’a eu lieu ; les transactions reflètent uniquement le vesting des RSU. Les RSU continueront de se vester à la date la plus proche entre la prochaine assemblée annuelle ou le premier anniversaire, sous condition de service.

À retenir pour les investisseurs : ce dépôt améliore la précision des informations sans impliquer de transactions en espèces ni modifier l’exposition économique globale de cet initié important.

GeneDx Holdings (WGS) – Geändertes Formular 4 (eingereicht am 25.07.08)

Direktor und 10%-Eigentümer Eli Casdin meldete die Vesting und sofortige Abwicklung von 12.924 RSUs am 18.06.25, die in Stammaktien der Klasse A mit Ausübungskosten von 0 $ umgewandelt wurden. Nach diesem Ereignis hält Casdin nun 20.518 Aktien direkt und über verschiedene verbundene Unternehmen 3,86 Millionen Aktien indirekt (3.507.164 über Casdin Partners Master Fund LP, 333.144 über CMLS Holdings LLC und 19.247 über Casdin Partners GP LLC).

Die Änderung korrigiert frühere administrative Fehler: Frühere Meldungen überschätzten die direkten Bestände um 1.376 Aktien und unterschätzten sie um 4.452 Aktien in verschiedenen Zeiträumen. Es gab keine Käufe oder Verkäufe am offenen Markt; die Transaktionen spiegeln ausschließlich das Vesting der RSUs wider. Die RSUs werden weiterhin zum früheren Zeitpunkt der nächsten Jahreshauptversammlung oder des einjährigen Jubiläums vesten, abhängig vom Dienstverhältnis.

Für Investoren: Die Meldung erhöht die Genauigkeit der Offenlegung, beinhaltet jedoch keine Bartransaktionen und ändert nicht die wirtschaftliche Gesamtexponierung dieses bedeutenden Insiders.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Casdin Eli

(Last) (First) (Middle)
1350 AVENUE OF THE AMERICAS
SUITE 2600

(Street)
NEW YORK NY 10019

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/23/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025(1) M 12,924 A $0(2) 20,518 D
Class A Common Stock 3,507,164 I See Casdin Partners Master Fund, LP(3)
Class A Common Stock 19,247 I See Casdin Partners GP, LLC(4)
Class A Common Stock 333,144 I See CMLS Holdings LLC(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 06/18/2025 A 3,576 (6) (6) Class A Common Stock 3,576 $0 3,576 D
Restricted Stock Unit (2) 06/18/2025 M 12,924 (6) (6) Class A Common Stock 12,924 $0 0 D
Explanation of Responses:
1. Due to clerical errors in prior filings, (i) the number of Class A Common Shares held directly by Eli Casdin was overstated by 1,376 shares in Form 4 filings filed from March 6th, 2024 through June 5th, 2024; and (ii) the Form 4 filed on August 5, 2024 understated Mr. Casdin's direct Class A Common Share holdings by 4,452 shares, as it did not reflect the correct total of 7,594 shares held directly following the vesting of 5,828 RSUs on June 20, 2024. These discrepancies in Class A Common Shares held by Eli Casdin have been corrected in subsequent filings.
2. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
3. The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
4. The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by Eli Casdin, the managing member of the GP.
5. The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings.
6. The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
Remarks:
This Form 4 is being amended to include footnote 1. The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ Eli Casdin, Eli Casdin 08/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eli Casdin report in the amended Form 4 for WGS?

He reported the vesting and settlement of 12,924 RSUs into Class A shares on 06-18-25.

How many GeneDx shares does Casdin now own directly?

After the transaction, he holds 20,518 Class A shares directly.

What is Casdin’s total indirect ownership in GeneDx?

Through affiliated entities he controls about 3.86 million additional shares.

Did the filing involve any cash purchases or sales?

No. The transactions were non-cash RSU conversions at $0 exercise price.

Why was the Form 4 amended?

To correct previous over- and under-statements of Casdin’s direct share count caused by clerical errors.

Do the corrected errors affect GeneDx’s financial statements?

The errors relate only to insider ownership records and do not impact the company’s financials.
GeneDx Holdings Corp

NASDAQ:WGS

WGS Rankings

WGS Latest News

WGS Latest SEC Filings

WGS Stock Data

3.06B
25.15M
12.46%
105.84%
12.12%
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD